Current Report Filing (8-k)
May 26 2017 - 4:17PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of
The
Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): May 25, 2017
CORBUS
PHARMACEUTICALS HOLDINGS, INC.
(Exact
name of registrant as specified in its charter)
|
Delaware
|
|
001-37348
|
|
46-4348039
|
|
(State
or other jurisdiction
|
|
(Commission
|
|
(IRS
Employer
|
|
of
incorporation)
|
|
File
Number)
|
|
Identification
No.)
|
|
100
River Ridge Drive, Norwood, MA
|
|
02062
|
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code:
(617) 963-0100
Not
Applicable
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
[ ]
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ]
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ]
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ]
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company [X]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [X]
Item
5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
On
May 25, 2017, Corbus Pharmaceuticals Holdings, Inc. (the “
Company
”) filed with the Secretary of State of Delaware
an amended and restated certificate of incorporation (the “
Restated Certificate
”), incorporating the amendments
to the Company’s certificate of incorporation, as amended, approved by the stockholders at the Company’s annual meeting
of the stockholders held on May 25, 2017 (the “
Annual Meeting
”), including (1) eliminating the ability of stockholders
to act by written consent and (2) eliminating the ability of stockholders to call special meetings. The Company’s stockholders
approved the Restated Certificate at the Annual Meeting, as more specifically described under Item 5.07 below. The Restated Certificate
was previously approved by the Board of Directors of the Company (the “
Board
”), subject to stockholder approval.
The foregoing summary of the Restated Certificate does not purport to be complete and is qualified in its entirety by reference
to the Restated Certificate, a copy of which is attached as Exhibit 3.1 to this Current Report on Form 8-K and is incorporated
by reference herein.
Effective
May 25, 2017, the Board adopted an amended and restated bylaws (the “
Restated Bylaws
”) (1) eliminating the
ability of stockholders to act by written consent and (2) eliminating the ability of stockholders to call special meetings. The
Board previously approved the Restated Bylaws subject to stockholder approval of the Restated Certificate. The foregoing summary
of the Restated Bylaws does not purport to be complete and is qualified in its entirety by reference to the Restated Bylaws, a
copy of which is attached as Exhibit 3.2 to this Current Report on Form 8-K and is incorporated by reference herein.
Item
5.07 Submission of Matters to a Vote of Security Holders.
On
May 25, 2017, the Company held the Annual Meeting. The matters voted on at the Annual Meeting were: (1) the election of directors,
(2) the adoption of an amendment to the Company’s certificate of incorporation, as amended, to eliminate the ability of
stockholders to act by written consent, (3) the adoption of an amendment to the Company’s certificate of incorporation,
as amended, to eliminate the ability of stockholders to call special meetings, (4) the adoption of an amended and restated certificate
of incorporation, which will incorporate the amendments proposed pursuant to the second and third proposals, if both of those
proposals are approved, and (5) the ratification of the appointment of EisnerAmper LLP as the Company’s independent registered
public accounting firm for the Company’s fiscal year ending December 31, 2017. The final voting results were as follows:
1.
The election of each of Dr. Yuval Cohen, Alan Holmer, David P. Hochman, Dr. Renu Gupta and Avery W. Catlin as directors to hold
office for a term of one year, until his or her successor is duly elected and qualified or he or she is otherwise unable to complete
his or her term.
The
votes were cast for this matter as follows:
|
Nominees
|
|
Votes For
|
|
Votes Withheld
|
|
Broker Non-Votes
|
|
Dr. Yuval Cohen
|
|
|
31,113,233
|
|
|
|
271,256
|
|
|
|
10,798,931
|
|
|
Alan Holmer
|
|
|
31,067,383
|
|
|
|
317,106
|
|
|
|
10,798,931
|
|
|
David P. Hochman
|
|
|
31,009,701
|
|
|
|
374,788
|
|
|
|
10,798,931
|
|
|
Dr. Renu Gupta
|
|
|
31,078,965
|
|
|
|
305,524
|
|
|
|
10,798,931
|
|
|
Avery W. Catlin
|
|
|
31,073,990
|
|
|
|
310,499
|
|
|
|
10,798,931
|
|
2.
The proposal to adopt an amendment to the Company’s certificate of incorporation, as amended, to eliminate the ability of
stockholders to act by written consent was approved based upon the following votes:
|
Votes For
|
|
Votes Against
|
|
Abstentions
|
|
Broker Non-Votes
|
|
29,345,422
|
|
|
1,834,946
|
|
|
|
204,121
|
|
|
|
10,798,931
|
|
3.
The proposal to adopt an amendment to the Company’s certificate of incorporation, as amended, to eliminate the ability of
stockholders to call special meetings was approved based upon the following votes:
|
Votes For
|
|
Votes Against
|
|
Abstentions
|
|
Broker Non-Votes
|
|
29,034,385
|
|
|
2,148,974
|
|
|
|
201,130
|
|
|
|
10,798,931
|
|
4.
The proposal to adopt an amended and restated certificate of incorporation, which will incorporate the amendments proposed pursuant
to the second and third proposals, if both of those proposals are approved, was approved based upon the following votes:
|
Votes For
|
|
Votes Against
|
|
Abstentions
|
|
Broker Non-Votes
|
|
29,233,658
|
|
|
1,768,628
|
|
|
|
382,203
|
|
|
|
10,798,931
|
|
5.
The proposal to ratify the appointment of EisnerAmper LLP as the Company’s independent registered public accounting firm
for the Company’s fiscal year ending December 31, 2017 was approved based upon the following votes:
|
Votes For
|
|
Votes Against
|
|
Abstentions
|
|
Broker Non-Votes
|
|
41,796,976
|
|
|
215,025
|
|
|
|
171,419
|
|
|
|
0
|
|
Item
9.01 Financial Statements and Exhibits
.
(d)
Exhibits.
|
Exhibit
No.
|
|
Description
|
|
|
|
|
|
3.1
|
|
Amended
and Restated Certificate of Incorporation of Corbus Pharmaceuticals Holdings, Inc., dated May 25, 2017
|
|
|
|
|
|
3.2
|
|
Amended
and Restated Bylaws of Corbus Pharmaceuticals Holdings, Inc., adopted May 25, 2017
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
|
CORBUS PHARMACEUTICALS HOLDINGS, INC.
|
|
|
|
|
|
Dated:
May 26, 2017
|
By:
|
/s/
Yuval Cohen
|
|
|
Name:
|
Yuval
Cohen
|
|
|
Title:
|
Chief
Executive Officer
|
EXHIBIT
INDEX
|
Exhibit
No.
|
|
Description
|
|
|
|
|
|
3.1
|
|
Amended
and Restated Certificate of Incorporation of Corbus Pharmaceuticals Holdings, Inc., dated May 25, 2017
|
|
|
|
|
|
3.2
|
|
Amended
and Restated Bylaws of Corbus Pharmaceuticals Holdings, Inc., adopted May 25, 2017
|
Corbus Pharmaceuticals (NASDAQ:CRBP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Corbus Pharmaceuticals (NASDAQ:CRBP)
Historical Stock Chart
From Jul 2023 to Jul 2024
